Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, summarizes his educational lecture on obesity, inflammation, and cancer—an important topic in oncology.
Jean-Charles Soria, MD, PhD, of Gustave Roussy, summarizes an important study: afatinib vs erlotinib in squamous cell carcinoma of the lung.
Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses the results from a phase III study investigating a multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic renal cell carcinoma (Abstract 17LBA).
Martine J. Piccart-Gebhart, MD, PhD, of the Jules Bordet Institute, and ECCO President, discusses ways in which imaging can form the solution to individualized cancer treatment.
Rolf A. Stahel, MD, of University Hospital, Zurich, discusses this phase II trial of erlotinib and bevacizumab in patients with advanced, EGFR-mutated non-small cell lung cancer without T790M mutation. The study was sponsored by The Spanish Lung Cancer Group and the European Thoracic Oncology Platform (Abstract 3BA).
Shailender Bhatia, MD, of the Fred Hutchinson Cancer Center, discusses his paper on interleukin-12 DNA and regression of Merkel cell tumors (Abstract 504).
